Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer Article

Industry Collaboration International Collaboration

cited authors

  • Paz-Ares, L.; Socinski, M. A.; Shahidi, J.; Hozak, R. R.; Soldatenkova, V.; Kurek, R.; Varella-Garcia, M.; Thatcher, N.; Hirsch, F. R.

authors

Publication Date

  • August 1, 2016

webpage

published in

category

keywords

  • EGFR expressing
  • SQUIRE
  • necitumumab
  • squamous NSCLC

start page

  • 1573

end page

  • 1579

volume

  • 27

issue

  • 8